Gentamicin
Apogen, Bristagen, Garamycin, Genoptic, Gentacidin, Gentafair, Gentak, Pred, U-gencin (gentamicin) is a small molecule pharmaceutical. Gentamicin was first approved as Garamycin on 1982-01-01. It is used to treat bacterial eye infections, bacterial infections, bacterial skin diseases, central nervous system infections, and endocarditis amongst others in the USA. It is known to target transient receptor potential cation channel subfamily A member 1.
Download report
Favorite
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Gentamicin sulfate
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
gentak | ANDA | 2022-01-28 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
bacterial eye infections | — | D015818 | — |
bacterial infections | — | D001424 | A49 |
bacterial skin diseases | — | D017192 | — |
central nervous system infections | EFO_1001456 | D002494 | A81 |
endocarditis | EFO_0000465 | D004696 | I33 |
escherichia coli infections | EFO_1001318 | D004927 | B96.20 |
infectious bone diseases | — | D001850 | — |
klebsiella infections | EFO_1001353 | D007710 | — |
proteus infections | EFO_1001130 | D011512 | — |
pseudomonas infections | EFO_0001076 | D011552 | — |
Show 6 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX07: Gentamicin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01G: Aminoglycoside antibacterials
— J01GB: Other aminoglycosides in atc
— J01GB03: Gentamicin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA11: Gentamicin
— S02: Otologicals
— S02A: Antiinfective drugs, otologic
— S02AA: Antiinfectives
— S02AA14: Gentamicin
— S03: Ophthalmological and otological preparations
— S03A: Antiinfectives, ophthalmologic and otologic
— S03AA: Antiinfectives
— S03AA06: Gentamicin
HCPCS
Code | Description |
---|---|
J1580 | Injection, garamycin, gentamicin, up to 80 mg |
Clinical
Clinical Trials
6 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Infections | D007239 | EFO_0000544 | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | — | 1 |
Rhinoscleroma | D012226 | EFO_0007470 | 1 | — | — | — | — | 1 | |
Communicable diseases | D003141 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | GENTAMICIN |
INN | gentamicin |
Description | Gentamicin is an antibiotic used to treat several types of bacterial infections. This may include bone infections, endocarditis, pelvic inflammatory disease, meningitis, pneumonia, urinary tract infections, and sepsis among others. It is not effective for gonorrhea or chlamydia infections. It can be given intravenously, by intramuscular injection, or topically. Topical formulations may be used in burns or for infections of the outside of the eye. It is often only used for two days until bacterial cultures determine what specific antibiotics the infection is sensitive to. The dose required should be monitored by blood testing.
|
Classification | Small molecule |
Drug class | antibiotics (Micromonospora strains) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CNC(C)[C@@H]1CC[C@@H](N)[C@@H](O[C@@H]2[C@@H](N)C[C@@H](N)[C@H](O[C@H]3OC[C@](C)(O)[C@H](NC)[C@H]3O)[C@H]2O)O1.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](C(C)N)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O.CN[C@@H]1[C@@H](O)[C@@H](O[C@@H]2[C@@H](O)[C@H](O[C@H]3O[C@H](CN)CC[C@H]3N)[C@@H](N)C[C@H]2N)OC[C@]1(C)O |
Identifiers
PDB | — |
CAS-ID | 1403-66-3 |
RxCUI | 1596450 |
ChEMBL ID | CHEMBL3039597 |
ChEBI ID | — |
PubChem CID | 3467 |
DrugBank | DB00798 |
UNII ID | T6Z9V48IKG (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
TRPA1
TRPA1
Organism
Homo sapiens
Gene name
TRPA1
Gene synonyms
ANKTM1
NCBI Gene ID
Protein name
transient receptor potential cation channel subfamily A member 1
Protein synonyms
ankyrin-like with transmembrane domains 1, Ankyrin-like with transmembrane domains protein 1, p120, Transformation-sensitive protein p120, Wasabi receptor
Uniprot ID
Mouse ortholog
Trpa1 (277328)
transient receptor potential cation channel subfamily A member 1 (Q8BLA8)
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
---|---|---|---|---|
VCV000009631 | MT-RNR1 | drug response | 2021-06-15 | 1A |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 122,731 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,289 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more